Novel Test for Improving Patient Outcomes in Hematologic Cancers. predictive test that determines sensitivity to therapeutic options
|
|
- Elvin Robertson
- 5 years ago
- Views:
Transcription
1 Novel Test for Improving Patient Outcomes in Hematologic Cancers predictive test that determines sensitivity to therapeutic options
2 Implementing A Surrogate Functional Biomarker Practical application of a fundamental biological principle to Guide Treatment Praedicare Dx: A predictive, functional biomarker platform that: Probes key cell death/survival mechanism cancer cells Measures function of Bcl-2 family onco-proteins ex vivo Provides CLIA validated test (LDT) headed towards IDE Demonstrated clinical utility in hematologic cancer Predictive Biomarker for AML, CLL, MM therapies Matches FDA paradigm for approval May provide Cdx for multiple therapies 2
3 Biomarker for Apoptosis-Inducing Therapies Test determines cancer cell proximity to programmed death Apoptosis Cell 1 Cell 2 Cell 3 Cell viability d x d y d z BCL Distinguishes Between: Sensitive cells Normal cells Resistant cells Cancer cells BCL Test readout (% priming [d x, d y, d z ] ) 3
4 Mitochondrial Profiling: Surrogate Functional Biomarker NORMAL CELL TUMOR CELL (addicted to anti-apoptotic proteins) Pro-apoptotic sensitizers and mimetic compounds are sequestered. Anti-apoptotic... Pro-apoptotic and sequester sensitizers proteins pro-apoptotic are and overexpressed mimetic activators, halting compounds tumor apoptosis. cells... displace activators, re-establishing the apoptotic pathway. LEGEND X APOPTOSIS Loss of Checkpoint Control DNA Damage Anaploidy X APOPTOSIS Mitochondrion Anti-Apoptotic Protein Pro-Apoptotic Protein Activator BH3 Protein Sensitizer BH3 Protein BH3 Mimetic Compound
5 Enhanced Decision Making in Hematologic Malignancy Apoptosis Drug Targets BCL2 AKT Mcl-1 PARP1 p53 PI3Kinase HDAC CDK Btk Proteasome Other SOC chemotherapies PraediCare Dx Hematological Malignancies MM AML ALL CLL NHL MCL DLBCL Broad Cdx Applications Improved Clinical Outcomes >450,000 US patients; >570,000 in EU 5
6 Complex Therapeutic Decision Making with Uncertain Efficacy and Certain Toxicity Objective: Make First Treatment the Best Treatment Identify non-responder patients and provide predictive value for alternative treatment option. AML Treatment Algorithm Age <60? Yes No Induction Standard Induction OR CR Transplant CR Consolidation Induction Failure Low-Intensity Therapy OR Intermediate- Intensity Therapy Induction Failure Retreatment OR Transplant Retreatment OR Transplant OR OR Best Supportive Care Transplant OR Best Supportive Care Best Supportive Care Adapted from NCCN Guidelines, Version , AML Today we have limited tools to predict patient outcomes in hematologic malignancy. A predictive diagnostic would have immediate and meaningful medical utility. - K. Anderson, MD Dana Farber Cancer Institute 6
7 Clinical Diagnostic: Establishing Evidence of Utility Acute Myeloid Leukemia Cytarabine - 62 patient Validation set completed Cytarabine patient Verification set started HMA - 28 patient Test set completed HMA patient Verification set started Alvocidib patient Validation study started Prospective study protocol to FDA AML - Cytarabine Response Predictor Multiple Myeloma Bortezomib - 25 patient Test set completed Carfilzomib patient (SWOG study started) Chronic Lymphocytic Leukemia Alvocidib - 65 patient Test set completed Ibrutinib+Alvocidib patient Validation study started Rituxan-125 patient Test set completed 7
8 PraediCare Dx development of test platform readout correlate to hypomethylating agent treatment In collaboration with Dr. Raoul Tibes at Mayo Scottsdale
9 Recent Eutropics Publications Demonstrate Medical and Pre-clinical Development Utility 9
10 PraediCare Dx Discriminates Positive and Adverse Response in CLL Hrk peptide readout predicts CLL patient response to alvocidib Bad peptide readout predicts adverse CLL patient response (TLS) to alvocidib AUC Bad =. 75 (p =.0007) AUC Bad+Age+ECOG =.85 (p <.0001) AUC Hrk =. 73 (p =.0002) AUC BIM(0.1) =. 73 (p =.0004) AUC Hrk+Trisomy12 =.83 (p <.0001) In collaboration with Dr. John Byrd and Dr. Amy Johnson Ohio State University, Division of Medical Oncology 10
11 Clinical Diagnostic: Guiding treatment decisions for SOC, SOC+, New treatments Report Date 08/22/13 Patient name John A. Smith Diagnosis Acute Myelogenous Leukemia Date of Birth 01/15/43 Client MD Anderson Sample Received 08/20/13 Gender Male Physician Dr. Jones Collection Method Whole blood ID# AB12345 Pathologist Dr. Springer Sample Date 08/19/13 Patient Results BIM BIM(.1) PUMA PUMA(10) PUMA 2A NOXA BMF BAD HRK Therapeutic Implications 65% Therapy #1 65% Likelihood of response 0% 100% 33% Therapy #2 33% Likelihood of response 0% 100% 85% Therapy #3 85% Likelihood of response 0% 100% 65% Therapy #4 65% Likelihood of response 0% 100% 15% Therapy #5 15% Likelihood of response 0% 100% 11
12 Utility of Predictive Test Clinical Therapeutic Medical utility for a range of indications MM AML CLL DLBCL NSCLC Garner Patient advocacy group support, uptake with KOLs, MolDx, reimbursement, NCCN, et.et. + Companion Diagnostic Benefit to Pharma Partners Clinical Development Speed development Regulatory Approval FDA compliance Commercial Competitive advantage Reimbursement Improve cost effectiveness, clinical outcomes 12
13 Path to Cdx Strategic plan to Cdx: Staged approach to building clinical product, Development Milestones CLIA(RUO) Relapsed/refractory patients IDE PMA: time frame Bridge study towards PMA (to be determined) True Cdx Concerns? Define risk mitigation strategy, Third party CLIA lab with larger footprint Deployment; commercialization and global distribution, with third party (could be required) Alignment on scalability and global footprint; 13
14 Will CDx Test Require IDE? Draft Guidance - In Vitro Companion Diagnostic Devices, August 2014 Investigational status: Use in clinical trials is typically considered investigational Does not matter even if already being previously provided as LDT (e.g., PraediCareDx) When a test is to be in a clinical study constitutes a significant risk study, an IDE must be filed For CDx, determination of significant risk relates to: Selection trial is considered a likely significant risk (SR) Stratification Trial: Likely non-significant risk (NSR) FDA (CDRH/OIR) is currently developing a Guidance Document on Use of Investigational Devices in Therapeutic Trials 14
15 Determining Risk in Drug-CDx studies CDRH Questions to Consider 1. Will use of the investigational test results lead to some trial subjects foregoing or delaying a treatment that is known to be effective? 1. Will use of the investigational test results expose trial subjects to safety risks that exceed the risks encountered with control therapies or non-trial standard of care? 2. Is it likely, based on a priori information about the investigational therapy, that incorrect test results would degrade the safety or efficacy of subjects treatment? 3. Does specimen acquisition, done for investigational testing and outside the standard of care, require an invasive sampling procedure that presents significant risk? Yes to any of the above questions results in the study be SR. No to all is NSR 15
16 Staged Cdx Development Praedicare Dx (AML): evidence based Path to CTA, Cdx; Perform test and training sets to establish correlation to response Perform verification in larger retrospective/prospective studies Perform Pilot prospective study in phase ½ or phase 2 clinical trial Lock down algorithm and analytics Perform Risk assessment, discussion with FDA; CEDR and CDRH Engage third party lab, transfer CLIA test (option) Select patients into phase 3 study 16
17 Reimbursement Considerations: Dx Evidence driven Coverage Coding Payment Analytical Validity: Accuracy, precision, and reproducibility Clinical Validity: Clinical Utility: Evidence Facilitate NCCN Guideline reference to support coverage) Use of Misc Chemistry code (84999) initially Multianalyte Assay with Algorithmic Analysis (MAAA) code once test is established Establish value-based list price (charges) for the test 17
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationPersonalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc
1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning
More information2/10/2017. Updates in Acute Leukemia Therapy Blood Cancer Incidence in the United States, Leukemia Incidence in the Unites States, 2016
Updates in Acute Leukemia Therapy 2017 Aaron Logan, MD, PhD UCSF Division of Malignant Hematology and Blood and Marrow Transplantation aaron.logan@ucsf.edu @hemedoc Blood Cancer Incidence in the United
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationFDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors
FDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors Diana Brixner, PhD, RPh, FAMCP Professor, University of Utah Health Sciences Executive Director, Pharmacotherapy Outcomes
More informationClinical Research in Medical Oncology
Clinical Research in Medical Oncology Adam M. Petrich, MD Northwestern University June 2, 2015 Objectives Why oncology? Why lymphoma? Why clinical research? Discuss various phases and objectives of clinical
More informationCorporate Medical Policy
Corporate Medical Policy Proteomics-based Testing Related to Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomics_based_testing_related_to_ovarian_cancer 7/2010
More informationSeptember 23, The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development
The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development September 23, 2016 Anand Pathak, MD, PhD, MPH Medical Officer Molecular Genetics Branch Division of Molecular Genetics and
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationMolecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018
Molecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018 Some Key Points Molecular Testing has applications in every section
More informationAre Payers Getting Tougher? Essential Insights on How to Smooth Acceptance of New Genetic Tests
Are Payers Getting Tougher? Essential Insights on How to Smooth Acceptance of New Genetic Tests Jacqueline Huang Senior Associate Reimbursement Policy and Government Affairs Objectives Learn how payers
More informationClinical Utility of Diagnostic Tests
Clinical Utility of Diagnostic Tests David A. Eberhard MD, PhD Director, Pre-Clinical Genomic Pathology, Lineberger Comprehensive Cancer Center Associate Professor, Depts. of Pathology and Pharmacology
More information[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016
[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationHow Personalized Medicine is Changing the Biopharmaceutical Marketplace
How Personalized Medicine is Changing the Biopharmaceutical Marketplace Marc Chioda, PharmD Associate Medical Director, Pfizer Oncology. Presentation to the Cancer Action Coalition of Virginia January
More informationDelivering on the Promise of Personalised Healthcare
Delivering on the Promise of Personalised Healthcare Dr John S Mills Diagnostic Team Director, Personalised Healthcare and Biomarkers Function, AstraZeneca, UK EBF 6 th Open Symposium, Barcelona, 20 Nov
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationDisrupting the Cell Cycle to Treat AML, MDS and other Cancers
CYC 682 Disrupting the Cell Cycle to Treat AML, MDS and other Cancers February 2015 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor provisions of
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationBuilding a Leading Oncology Franchise
Building a Leading Oncology Franchise January 2019 NASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are
More informationAcquisition of Tolero Pharmaceuticals, Inc. December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd.
Acquisition of Tolero Pharmaceuticals, Inc. December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Acquisition of Tolero Pharmaceuticals, Inc. Significance of the Acquisition Acquire attractive compounds
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More information5/13/2015. FDA Oversight and IRB Review of Studies that Include In-Vitro Diagnostics. Webinar Objectives
FDA Oversight and IRB Review of Studies that Include In-Vitro Diagnostics May 14, 2015 1:00-2:30 PM ET Jonathan Green, MD Washington University School of Medicine E. David Litwack, PhD US Food and Drug
More informationOpportunities and Challenges in the Development of Companion Diagnostics
Opportunities and Challenges in the Development of Companion Diagnostics E. Patrick Groody, Ph.D. Divisional Vice President Research and Development Abbott Molecular Agenda Value of Personalized Medicine
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationCollege of American Pathologists
College of American Pathologists Comments to the Food and Drug Administration on the draft guidance In Vitro Companion Diagnostics Devices October 12, 2011 College of American Pathologists 1350 I Street,
More informationImportance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine
Importance of Methodology Certification and Accreditations to Perform Assays Stan Hamilton, MD Head, Pathology and Laboratory Medicine 1 Disclosures No disclosures relevant to this presentation 2 A bad
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationUnderstanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine
Stamelos et al. Journal of Molecular Signaling 2012, 7:12 REVIEW Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine Vasileios A Stamelos
More informationCLL: future therapies. Dr. Nathalie Johnson
CLL: future therapies Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck Outline Treatment of relapsed
More informationActinium Pharmaceuticals, Inc.
, Inc. Actimab-A MRD Consolidation Strategy in MRD+ AML July 10, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or other forward-looking statements regarding
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More information11th Annual Population Health Colloquium. Stan Skrzypczak, MS, MBA Sr. Director, Marketing Genomic Health, Inc. March 15, 2011
11th Annual Population Health Colloquium Stan Skrzypczak, MS, MBA Sr. Director, Marketing Genomic Health, Inc. March 15, 2011 Agenda Personalized medicine in oncology healthcare Clinical relevance of personalized
More informationNGS Gateway Lab Services
TM NGS Gateway Lab Services Accelerating Precision Medicine Design a Complete Genomic Testing Portfolio with Turnkey Assays About NGS Gateway Lab Services TM Designed to provide a gateway to your own in-house
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationLung Cancer Screening
Lung Cancer Screening v Lung Cancer: America s leading cancer killer Annual US cancer mortality 158,040 221,000 new diagnoses in US 4,100 14,180 27,540 Lung 40,560 40,730 49,700 Cervix Ovary Prostate Pancreas
More informationDisruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationGENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA
CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationCorporate Presentation
Corporate Presentation January 2018 ASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are forward-looking
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationWho Pays for Personalized Medicine? A Conversation With Industry Insiders. July 15, 2010 Garden Court Hotel, Palo Alto
Who Pays for Personalized Medicine? A Conversation With Industry Insiders July 15, 2010 Garden Court Hotel, Palo Alto Speakers Aidan Toombs, Attorney, Crescendo Bioscience Judy Waltz, Partner and Co-Chair,
More informationStifel Healthcare Conference
Stifel Healthcare Conference ovember 2017 ASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are forward-looking
More informationLiver Forum Cirrhosis Working Group Arun J. Sanyal
Liver Forum Cirrhosis Working Group Arun J. Sanyal Z Reno Vlahcevic Professor of Medicine VCU School of Medicine Richmond, VA 2 Liver Forum 8 DRUG DEVELOPMENT PATHWAYS Regular approval pathway: based on
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationBLOOD AND LYMPH CANCERS
BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber
More informationIn this program you will learn
1 In this program you will learn How to gather information to help you make treatment decisions Questions to ask about the benefits and risks of any treatment How new blood cancer treatments are developed
More informationDelivering Value Through Personalized Medicine: An Industry Perspective
Delivering Value Through Personalized Medicine: An Industry Perspective Josephine A. Sollano, Dr.PH Head, Global HEOR and Medical Communications Pfizer Oncology, NY, USA josephine.sollano@pfizer.com What
More informationCarfilzomib for PTCL. Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center
Carfilzomib for PTCL Julie M. Vose, M.D., M.B.A. University of Nebraska Medical Center jmvose@unmc.edu A spectrum of mutations observed in AITL target NF-κB pathway GEP: Enrichment of NF-κB Pathway in
More informationVenetoclax in MCL. Prof. Le Gouill Nantes Medical University, France
Venetoclax in MCL Prof. Le Gouill Nantes Medical University, France Evasion of Apoptosis, or Cell Death, is 1. Resisting Cell Death 2. Sustained angiogenesis for growth and survival (primarily solid tumors)
More informationPRESAGE CIVO: A NOVEL PLATFORM FOR PRECISION ONCOLOGY & DRUG DEVELOPMENT
PRESAGE : A NOVEL PLATFORM FOR PRECISION ONCOLOGY & DRUG DEVELOPMENT DECEMBER 2017 Presage Biosciences, Inc. 2017. All rights reserved. Presage Proprietary Biosciences, information. Inc. 2017. All rights
More information7 Recruiting Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Condition: Waldenstrom's Macroglobulinemia
1 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom and Related Disorders Conditions: Multiple Myeloma; Waldenstrom's ; Smoldering Multiple Myeloma; Lymphoblastic Lymphoma Intervention:
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More information[ NASDAQ: MEIP ] Stifel Healthcare Conference November 15-16, 2016
[ NASDAQ: MEIP ] Stifel Healthcare Conference November 15-16, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results
More informationHow the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More informationClinical Trial News on the Treatment of Waldenstrom s Macroglobulinemia
Clinical Trial News on the Treatment of Waldenstrom s Macroglobulinemia Edward Libby M.D. Associate Professor, University of Washington Department of Medicine, Division of Medical Oncology Fred Hutchinson
More informationTranslating cancer biology into medicines Noble Capital Markets Conference NASDAQ CYCC - January 30, 2018
CYC 682 Translating cancer biology into medicines Noble Capital Markets Conference NASDAQ CYCC - January 30, 2018 Disclaimer This presentation contains forward-looking statements within the meaning of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationAccelerating Translation at Dana-Farber Cancer Institute*
Accelerating Translation at Dana-Farber Cancer Institute* *and our partner institutions February 12, 2013 Edward J Benz JR, MD Dana Farber Cancer Institute 1 2 Academic Structure All Dana-Farber faculty
More informationSelective Bcl-2 Inhibition to Treat Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Selective Bcl-2 Inhibition to Treat Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma Samuel Y. Ng, MD, PhD, and Matthew S. Davids, MD Dr Ng is a clinical fellow and Dr Davids is an attending physician
More informationNew and Emerging Strategies in the Treatment of Patients with Higher risk Myelodysplastic Syndromes (MDS)
Welcome to Managing Myelodysplastic Syndromes. My name is David Steensma. I am an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Adult Leukemia Program at Dana Farber
More informationUS Regulatory Considerations for Therapeutic Cancer Vaccines
US Regulatory Considerations for Therapeutic Cancer Vaccines Peter Bross, M.D., Team Leader, Clinical Oncology, FDA Center for Biologics Evaluation and Research 1 Immune Therapies: The Future Is Now Tuesday,
More informationDecember 13, The Future Reimbursement Environment for NGS for Oncology
WELCOME! Today s Speaker Mr. Mathews has worked on a variety of diagnostic reimbursement projects involving the analysis, development, and implementation of coding, coverage, and payment strategies for
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Venclexta) Reference Number: CP.PHAR.129 Effective Date: 07.17.18 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationSTEMCENTRX ACQUISITION. April 28, 2016
STEMCENTRX ACQUISITION April 28, 2016 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private Securities
More informationNeedham Healthcare Conference
Needham Healthcare Conference April 4, 2017 NASDAQ: MEIP Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationActinium Pharmaceuticals, Inc. Leveraging the strengths of Antibody Radiation Conjugates to build the Best in Class CD33 Program
, Inc. Leveraging the strengths of Antibody Radiation Conjugates to build the Best in Class CD33 Program 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationNeedham Healthcare Conference. April 4, 2017
Needham Healthcare Conference April 4, 2017 Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The
More informationKey CDRH Regulatory Initiatives
Key CDRH Regulatory Initiatives Revamping the Submission Process Creating New Strategies Ralph F. Hall University of Minnesota Law School Counsel Faegre Baker & Daniels May 8, 2012 Purpose of Today s Program
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationOraSure Technologies. JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014
OraSure Technologies JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014 Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including
More informationGLOBAL REGISTRATION STRATEGIES:
GLOBAL REGISTRATION STRATEGIES: Therapeutic Product (TP) and the Companion Diagnostic (CDx) Erin Pedalino Regulatory Affairs International MSD Unique Role as CDx Regulatory Liaison at a Therapeutic Product
More informationGuardant Health Investor Presentation. January 2019
Guardant Health Investor Presentation January 2019 Safe harbor statement This presentation contains forward-looking statements, which are statements related to future events that by their nature address
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationPersonalizing Myeloma Treatment Drugs and Strategies
Personalizing Myeloma Treatment Drugs and Strategies PD Dr. med. Marc S. Raab Heidelberg University Medical Center & German Cancer Research Center Multiple Myeloma Clonal proliferation of malignant plasma
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationBCL-2 as therapeutic target for hematological malignancies
Perini et al. Journal of Hematology & Oncology (2018) 11:65 https://doi.org/10.1186/s13045-018-0608-2 REVIEW BCL-2 as therapeutic target for hematological malignancies Guilherme Fleury Perini 1, Glaciano
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationClinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: Last Review Date: 11.18
Clinical Policy: (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: 02.01.17 Last Review Date: 11.18 Coding Implications Revision Log Line of Business: Medicaid, HIM-Medical Benefit See Important
More information